Cyclins and their related proteins in pituitary tumourigenesis

Molecular and Cellular Endocrinology

Volumn 326, Issue 1-2, 2010, Pages 25-29

  Muşat, Mǎdǎlina ^a   Morris, Damian G ^c   Korbonits, Márta ^b   Grossman, Ashley B ^b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c IPSWICH HOSPITAL   (United Kingdom)

Author keywords

Ago; Cell cycle; Cyclin; P16; P18; P27; Pituitary tumours; Proteasome

Indexed keywords

ARGONAUTE 1 PROTEIN; ARGONAUTE 2 PROTEIN; BETA CATENIN; CORTICOTROPIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; GROWTH HORMONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PITUITARY TUMOR TRANSFORMING PROTEIN; PROLACTIN; PROTEIN KINASE B; PROTEIN P16; PROTEIN P27; PROTEIN P57; RETINOBLASTOMA PROTEIN; SECURIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACTH SECRETING ADENOMA; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; DNA METHYLATION; ENDOCRINE DISEASE; ENZYME ACTIVATION; FRAMESHIFT MUTATION; GENE EXPRESSION; GROWTH HORMONE SECRETING ADENOMA; HETEROZYGOSITY LOSS; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MALIGNANT TRANSFORMATION; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

CELL CYCLE PROTEINS; CYCLIN E; CYCLIN-DEPENDENT KINASES; CYCLINS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASMS; PITUITARY GLAND; PITUITARY NEOPLASMS;

EID: 77955322554     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.03.017     Document Type: Article

References (60)

1. Agarwal S.K., Mateo C.M., Marx S.J. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab. 2009, 94:1826-1834.
2. Arzt E., Chesnokova V., Stalla G.K., Melmed S. Pituitary adenoma growth: a model for cellular senescence and cytokine action. Cell Cycle 2009, 8:677-678.
3. Bai F., Pei X.H., Nishikawa T., Smith M.D., Xiong Y. p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol. Cell. Biol. 2007, 27:1495-1504.
4. Bamberger C.M., Fehn M., Bamberger A.M., Ludecke D.K., Beil F.U., Saeger W., Schulte H.M. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur. J. Endocrinol. 1999, 140:250-255.
5. Bashir T., Pagano M. Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis. Adv. Cancer Res. 2003, 88:101-144.
6. Bates A.S., Farrell W.E., Bicknell E.J., McNicol A.M., Talbot A.J., Broome J.C., Perrett C.W., Thakker R.V., Clayton R.N. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J. Clin. Endocrinol. Metab. 1997, 82:818-824.
7. Besson A., Hwang H.C., Cicero S., Donovan S.L., Gurian-West M., Johnson D., Clurman B.E., Dyer M.A., Roberts J.M. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 2007, 21:1731-1746.
8. Bilodeau S., Roussel-Gervais A., Drouin J. Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells. Mol. Cell Biol. 2009, 29:1895-1908.
9. Burgess J.R., Nord B., David R., Greenaway T.M., Parameswaran V., Larsson C., Shepherd J.J., Teh B.T. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clin. Endocrinol. (Oxf.) 2000, 53:205-211.
10. Clurman B.E., Sheaff R.J., Thress K., Groudine M., Roberts J.M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996, 10:1979-1990.
11. Dahia P.L., Aguiar R.C., Honegger J., Fahlbush R., Jordan S., Lowe D.G., Lu X., Clayton R.N., Besser G.M., Grossman A.B. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 1998, 16:69-76.
12. Dworakowska D., Wlodek E., Leontiou C.A., Igreja S., Cakir M., Teng M., Prodromou N., Goth M.I., Grozinsky-Glasberg S., Gueorguiev M., Kola B., Korbonits M., Grossman A.B. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer 2009, 16:1329-1338.
13. Elston M.S., Gill A.J., Conaglen J.V., Clarkson A., Shaw J.M., Law A.J., Cook R.J., Little N.S., Clifton-Bligh R.J., Robinson B.G., McDonald K.L. Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 2008, 149:1235-1242.
14. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Firpo E., Polyak K., Tsai L.H., Broudy V., Perlmutter R.M., Kaushansky K., Roberts J.M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996, 85:733-744.
15. Franklin D.S., Godfrey V.L., Lee H., Kovalev G.I., Schoonhoven R., Chen-Kiang S., Su L., Xiong Y. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998, 12:2899-2911.
16. Franklin D.S., Godfrey V.L., O'Brien D.A., Deng C., Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol. 2000, 20:6147-6158.
17. Gazioglu N.M., Erensoy N., Kadioglu P., Sayitoglu M.A., Ersoy I.H., Hatirnaz O., Kisacik B., Oz B., Sar M., Ozbek U., Ciplak N., Cagatay P. Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas. Med. Sci. Monit. 2007, 13:CR457-CR463.
18. Georgitsi M., Raitila A., Karhu A., van der Luijt R.B., Aalfs C.M., Sane T., Vierimaa O., Makinen M.J., Tuppurainen K., Paschke R., Gimm O., Koch C.A., Gundogdu S., Lucassen A., Tischkowitz M., Izatt L., Aylwin S., Bano G., Hodgson S., De Menis E., Launonen V., Vahteristo P., Aaltonen L.A. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 2007, 92:3321-3325.
19. Gueorguiev M., Grossman A.B. Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis. Pituitary 2009, 12:245-255.
20. Hai N., Aoki N., Shimatsu A., Mori T., Kosugi S. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clin. Endocrinol. (Oxf.) 2000, 52:509-518.
21. Hibberts N.A., Simpson D.J., Bicknell J.E., Broome J.C., Hoban P.R., Clayton R.N., Farrell W.E. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 1999, 5:2133-2139.
22. Hu N., Gutsmann A., Herbert D.C., Bradley A., Lee W.H., Lee E.Y. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994, 9:1021-1027.
23. Igreja S., Chahal H.S., Akker S.A., Gueorguiev M., Popovic V., Damjanovic S., Burman P., Wass J.A., Quinton R., Grossman A.B., Korbonits M. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin. Endocrinol. (Oxf.) 2009, 70:259-264.
24. Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A., Weinberg R.A. Effects of an Rb mutation in the mouse. Nature 1992, 359:295-300.
25. Jordan S., Lidhar K., Korbonits M., Lowe D.G., Grossman A.B. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 2000, 143:R1-R6.
26. Koepp D.M., Schaefer L.K., Ye X., Keyomarsi K., Chu C., Harper J.W., Elledge S.J. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001, 294:173-177.
27. Korbonits M., Chahal H.S., Kaltsas G., Jordan S., Urmanova Y., Khalimova Z., Harris P.E., Farrell W.E., Claret F.X., Grossman A.B. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J. Clin. Endocrinol. Metab. 2002, 87:2635-2643.
28. Lidhar K., Korbonits M., Jordan S., Khalimova Z., Kaltsas G., Lu X., Clayton R.N., Jenkins P.J., Monson J.P., Besser G.M., Lowe D.G., Grossman A.B. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J. Clin. Endocrinol. Metab. 1999, 84:3823-3830.
29. Mamillapalli R., Gavrilova N., Mihaylova V.T., Tsvetkov L.M., Wu H., Zhang H., Sun H. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. 2001, 11:263-267.
30. Marini F., Falchetti A., Del Monte F., Carbonell S.S., Gozzini A., Luzi E., Brandi M.L. Multiple endocrine neoplasia type 1. Orphanet. J. Rare Dis. 2006, 1:38.
31. Moberg K.H., Bell D.W., Wahrer D.C., Haber D.A., Hariharan I.K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 2001, 413:311-316.
32. Morris D.G., Musat M., Czirjak S., Hanzely Z., Lillington D.M., Korbonits M., Grossman A.B. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur. J. Endocrinol. 2005, 153:143-151.
33. Musat M., Korbonits M., Pyle M.E., Gueorguiev M., Kola B., Morris D.G., Powell M.P., Dumitrache C., Poiana C., Grossman A.B. The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors. Pituitary 2002, 5:235-242.
34. Musat M., Korbonits M., Kola B., Borboli N., Hanson M.R., Nanzer A.M., Grigson J., Jordan S., Morris D.G., Gueorguiev M., Coculescu M., Basu S., Grossman A.B. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr. Relat. Cancer 2005, 12:423-433.
35. Musat M., Vax V.V., Borboli N., Gueorguiev M., Bonner S., Korbonits M., Grossman A.B. Cell cycle dysregulation in pituitary oncogenesis. Front. Horm. Res. 2004, 32:34-62.
36. Neto A.G., McCutcheon I.E., Vang R., Spencer M.L., Zhang W., Fuller G.N. Elevated expression of p21 (WAF1/Cip1) in hormonally active pituitary adenomas. Ann. Diagn. Pathol. 2005, 9:6-10.
37. Nguyen H., Gitig D.M., Koff A. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol. Cell. Biol. 1999, 19:1190-1201.
38. Ogino A., Yoshino A., Katayama Y., Watanabe T., Ota T., Komine C., Yokoyama T., Fukushima T. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. J. Neuropathol. Exp. Neurol. 2005, 64:398-403.
39. Owens M., Stals K., Ellard S., Vaidya B. Germline mutations in the CDKN1B gene encoding p27 Kip1 are a rare cause of multiple endocrine neoplasia type 1. Clin. Endocrinol. (Oxf.) 2009, 70:499-500.
40. Ozawa A., Agarwal S.K., Mateo C.M., Burns A.L., Rice T.S., Kennedy P.A., Quigley C.M., Simonds W.F., Weinstein L.S., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J. Clin. Endocrinol. Metab. 2007, 92:1948-1951.
41. Pei L., Melmed S., Scheithauer B., Kovacs K., Benedict W.F., Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res. 1995, 55:1613-1616.
42. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., Fend F., Graw J., Atkinson M.J. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:15558-15563.
43. Pyle M.E., Korbonits M., Gueorguiev M., Jordan S., Kola B., Morris D.G., Meinhardt A., Powell M.P., Claret F.X., Zhang Q., Metz C., Bucala R., Grossman A.B. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J. Endocrinol. 2003, 176:103-110.
44. Qian X., Jin L., Grande J.P., Lloyd R.V. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996, 137:3051-3060.
45. Quereda V., Malumbres M. Cell cycle control of pituitary development and disease. J. Mol. Endocrinol. 2009, 42:75-86.
46. Ribeiro-Oliveira A., Franchi G., Kola B., Dalino P., Pinheiro S., Salahuddin N., Musat M., Goth M., Czirjak S., Hanzely Z., Silva D., Paulino E., Grossman A., Korbonits M. Protein western array analysis in human pituitary tumours: insights and limitations. Endocr. Relat. Cancer 2008.
47. Scheithauer B.W., Laws E.R., Kovacs K., Horvath E., Randall R.V., Carney J.A. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin. Diagn. Pathol. 1987, 4:205-211.
48. Shirane M., Harumiya Y., Ishida N., Hirai A., Miyamoto C., Hatakeyama S., Nakayama K., Kitagawa M. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 1999, 274:13886-13893.
49. Simpson D.J., Bicknell J.E., McNicol A.M., Clayton R.N., Farrell W.E. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer 1999, 24:328-336.
50. Simpson D.J., Frost S.J., Bicknell J.E., Broome J.C., McNicol A.M., Clayton R.N., Farrell W.E. Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 2001, 22:1149-1154.
51. Simpson D.J., Hibberts N.A., McNicol A.M., Clayton R.N., Farrell W.E. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 2000, 60:1211-1216.
52. Simpson D.J., Magnay J., Bicknell J.E., Barkan A.L., McNicol A.M., Clayton R.N., Farrell W.E. Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas. Cancer Res. 1999, 59:1562-1566.
53. Strohmaier H., Spruck C.H., Kaiser P., Won K.A., Sangfelt O., Reed S.I. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001, 413:316-322.
54. Thakker R.V. Multiple endocrine neoplasia-syndromes of the twentieth century. J. Clin. Endocrinol. Metab. 1998, 83:2617-2620.
55. Tolkacheva T., Boddapati M., Sanfiz A., Tsuchida K., Kimmelman A.C., Chan A.M. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 2001, 61:4985-4989.
56. Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997, 16:5334-5344.
57. Waite K.A., Eng C. BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum. Mol. Genet. 2003, 12:679-684.
58. Woloschak M., Yu A., Post K.D. Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol. Carcinog. 1997, 19:221-224.
59. Wu G., Mambo E., Guo Z., Hu S., Huang X., Gollin S.M., Trink B., Ladenson P.W., Sidransky D., Xing M. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J. Clin. Endocrinol. Metab. 2005, 90:4688-4693.
60. Yoshino A., Katayama Y., Ogino A., Watanabe T., Yachi K., Ohta T., Komine C., Yokoyama T., Fukushima T. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. J. Neurooncol. 2007, 83:153-162.